For 4QCY2016, Sanofi India posted results which were below expectations on the
sales front. The sales came in at Rs552cr v/s. Rs570cr expected, posting a yoy
growth of 5.6%. On the operating front, the EBITDA margin came in at 12.2%
(12.3% expected) v/s. 12.7% in 4QCY2015. This came in-spite of GPM (Gross
Profit Margin), which came in at 54.7% V/s 51.5% in 4QCY2016, as the other
expenses rose by 28.5% yoy. Consequently, the Adj. PAT came in at Rs51cr v/s.
Rs53cr in 4QCY2015, a yoy de-growth of 3.8%. This was against the expectations
of Rs50cr. We maintain our Neutral rating on the stock.
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...
Please Wait...